SLN312

SLN312 is an investigational RNA interference (RNAi) therapeutic developed by Silence Therapeutics. It is designed as a small interfering RNA (siRNA) drug, though its precise molecular target and primary indication have not been publicly disclosed as of June 2025. The drug is in early-stage clinical development, with the highest reported global R&D status being Phase 1. Silence Therapeutics’ pipeline focuses on hematology, cardiovascular disease, and rare diseases; however, for SLN312 specifically, available data indicate it is being investigated for nervous system diseases[1][2][5]. The mechanism of action involves gene silencing via RNA interference.